IP Library › Granted Patent US 12,582,586
Granted Patent B2
US 12,582,586 · App. 18/732,903 · Granted Mar 24, 2026

Oral care compositions

Inventors: Aarti Rege (East Windsor, NJ); Michael Prencipe (West Windsor, NJ)
Assignee: Colgate-Palmolive Company
A61K8/27A61K8/19A61K8/20A61K8/21A61K8/24A61K8/362A61Q11/00A61K2800/28A61K2800/48A61K2800/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,586
App. No.
18/732,903
Granted
Mar 24, 2026
Kind
B2
Abstract

An oral care composition comprising high water oral care compositions comprising an orally acceptable carrier, zinc phosphate, a first stannous ion source (i.e., stannous fluoride), and a second stannous ion source (i.e., stannous chloride). Methods and uses for this composition are also described throughout.

Claims (21)

1 . An oral care composition comprising:

an orally acceptable carrier;

zinc phosphate present in an amount of from about 0.05 wt. % to about 10 wt. %;

a first stannous ion source comprising stannous fluoride present in an amount of from about 0.01 wt. % to about 5 wt. %;

a second stannous ion source comprising stannous chloride present in an amount from about 0.01 wt. % to about 5 wt. %;

water present in an amount of 15 wt. % or more; and

one or more surfactants selected from sodium lauryl sulfate, sodium laureth sulfate, or cocamidopropyl betaine, and combinations thereof;

wherein all weight percentages are based on the total weight of the oral care composition.

2 . A composition according to claim 1 , wherein the zinc phosphate is a preformed salt of zinc phosphate.

3 . A composition according to claim 1 , wherein the amount of zinc phosphate is present in an amount of from 0.1 to 8% by weight.

4 . A composition according to claim 1 , wherein the amount of the first stannous ion source is from 0.05% to 4% by weight.

5 . A composition according to claim 1 , wherein the amount of the second stannous ion source is from 0.05% to 4% by weight.

6 . A composition according to claim 1 , wherein the amount of the water is 15-90 wt. %.

7 . A composition according to claim 1 , further comprising one or more humectants selected from sorbitol, glycerol, xylitol and propylene glycol, and combinations thereof.

8 . A composition according to claim 1 , further comprising an effective amount of one or more alkali phosphate salts selected from orthophosphates, pyrophosphates, tripolyphosphates, tetraphosphates and higher polyphosphates.

9 . A composition according to claim 8 , wherein the alkali phosphate salts comprise tetrasodium pyrophosphate or tetrapotassium pyrophosphate.

10 . A composition according to claim 1 , further comprising one or more sources of zinc ions in addition to the zinc phosphate.

11 . A composition according to claim 1 , further comprising an organic acid buffer system comprising a carboxylic acid and one or more conjugate base salts thereof.

12 . A composition according to claim 1 , wherein the oral care composition is a dentifrice.

13 . A method of treatment or prevention of erosive tooth demineralization, gingivitis, plaque, and/or dental caries, the method comprising the application to the oral cavity of a person in need thereof a composition according to claim 1 , one or more times per day.

14 . A method to (i) reduce or inhibit formation of dental caries, (ii) reduce, repair or inhibit pre-carious lesions of the enamel, (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial biofilm formation in the oral cavity, (x) raise and/or maintain plaque pH at levels of at least pH 5.5 following sugar challenge, (xi) reduce plaque accumulation, (xii) treat, relieve or reduce dry mouth, (xiii) clean the teeth and oral cavity (xiv) reduce erosion, (xv) prevents stains and/or whiten teeth, (xvi) immunize the teeth against cariogenic bacteria; and/or (xvii) promote systemic health, including cardiovascular health the method comprising applying an effective amount of the oral composition according to claim 1 to a surface of an oral cavity in need thereof.

Continuity (7)
Continuation 17249912 · Mar 18, 2021
Continuation 16992718 · Aug 13, 2020
Continuation 16708646 · Dec 10, 2019
Continuation 16376185 · Apr 5, 2019
Continuation 15674719 · Aug 11, 2017
Provisional Application 62437102 · Dec 21, 2016
Related Publication 20240315934A1 · Sep 26, 2024
References Cited (57)
US 3535421A · Briner et al. · 1970 [cited by applicant]
US 3538230A · Morton et al. · 1970 [cited by applicant]
US 3678154A · Widder et al. · 1972 [cited by applicant]
US 3746555A · Muhler · 1973 [cited by applicant]
US 3862307A · Di Giulio · 1975 [cited by applicant]
US 3937807A · Haefele · 1976 [cited by applicant]
US 3959458A · Agricola et al. · 1976 [cited by applicant]
US 4022880A · Mnson et al. · 1977 [cited by applicant]
US 4051234A · Gieske et al. · 1977 [cited by applicant]
US 4340583A · Wason · 1982 [cited by applicant]
US 4866161A · Sikes et al. · 1989 [cited by applicant]
US 4885155A · Parran, Jr. et al. · 1989 [cited by applicant]
US 5004597A · Majeti et al. · 1991 [cited by applicant]
US 5188821A · Gaffar et al. · 1993 [cited by applicant]
US 5192531A · Gaffar et al. · 1993 [cited by applicant]
US 5578293A · Prencipe et al. · 1996 [cited by applicant]
US 6221340B1 · Yu et al. · 2001 [cited by applicant]
US 8216553B2 · Hughes et al. · 2012 [cited by applicant]
US 9314419B2 · Lin et al. · 2016 [cited by applicant]
US 9968803B2 · Fruge et al. · 2018 [cited by applicant]
US 10098822B2 · Rege et al. · 2018 [cited by applicant]
US 10154948B2 · Vemishetti et al. · 2018 [cited by applicant]
US 10172770B2 · Rege · 2019 [cited by applicant]
US 10213368B2 · Li et al. · 2019 [cited by applicant]
US 10278906B2 · Rege et al. · 2019 [cited by applicant]
US 10285919B2 · Rege et al. · 2019 [cited by applicant]
US 10524990B2 · Rege · 2020 [cited by applicant]
US 10524991B2 · Rege et al. · 2020 [cited by applicant]
US 10576029B2 · Rege et al. · 2020 [cited by applicant]
US 10736828B2 · Rege et al. · 2020 [cited by applicant]
US 10772809B2 · Rege et al. · 2020 [cited by applicant]
US 10980720B2 · Rege et al. · 2021 [cited by applicant]
US 11998625B2 · Rege et al. · 2024 [cited by applicant]
US 20030206874A1 · Doyle et al. · 2003 [cited by applicant]
US 20050180927A1 · Aldous et al. · 2005 [cited by applicant]
US 20070025928A1 · Glandorf et al. · 2007 [cited by applicant]
US 20110020248A1 · Strand · 2011 [cited by applicant]
US 20130224270A1 · Robinson et al. · 2013 [cited by applicant]
US 20150305993A1 · Rege et al. · 2015 [cited by applicant]
US 20150320655A1 · Li et al. · 2015 [cited by applicant]
US 20170367949A1 · Rege et al. · 2017 [cited by applicant]
US 20190133903A1 · Vemishetti et al. · 2019 [cited by applicant]
US 20190192394A1 · Rege et al. · 2019 [cited by applicant]
US 20190192395A1 · Rege et al. · 2019 [cited by applicant]
US 20200155427A1 · Rege et al. · 2020 [cited by applicant]
US 20200253844A1 · Rege et al. · 2020 [cited by applicant]
US 20200297597A1 · Rege et al. · 2020 [cited by applicant]
US 20200330345A1 · Rege et al. · 2020 [cited by applicant]
CA 2634758 · 2007 [cited by applicant]
CN 101330900 · 2008 [cited by applicant]
CN 101479009 · 2009 [cited by applicant]
CN 103140209 · 2013 [cited by applicant]
CN 104822361 · 2015 [cited by applicant]
RU 2469700 · 2012 [cited by applicant]
WO 2009060385 · 2009 [cited by applicant]
WO 2014088573A1 · 2014 [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2017/046424, mailed Oct. 13, 2017. [cited by applicant]